GENMAB A/S -SP ADR (GMAB) Fundamental Analysis & Valuation

NASDAQ:GMAB • US3723032062

Current stock price

25.1 USD
-0.63 (-2.45%)
At close:
24.6 USD
-0.5 (-1.99%)
Pre-Market:

This GMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GMAB Profitability Analysis

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • In the past year GMAB had a positive cash flow from operations.
  • GMAB had positive earnings in each of the past 5 years.
  • GMAB had a positive operating cash flow in each of the past 5 years.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 7.48%, GMAB belongs to the best of the industry, outperforming 92.49% of the companies in the same industry.
  • With an excellent Return On Equity value of 16.47%, GMAB belongs to the best of the industry, outperforming 94.03% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 9.04%, GMAB belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for GMAB is significantly below the industry average of 18.89%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • GMAB's Profit Margin of 25.89% is amongst the best of the industry. GMAB outperforms 93.83% of its industry peers.
  • GMAB's Profit Margin has declined in the last couple of years.
  • The Operating Margin of GMAB (33.60%) is better than 96.34% of its industry peers.
  • GMAB's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 93.60%, GMAB belongs to the best of the industry, outperforming 94.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GMAB Health Analysis

2.1 Basic Checks

  • GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, GMAB has less shares outstanding
  • GMAB has less shares outstanding than it did 5 years ago.
  • GMAB has a worse debt/assets ratio than last year.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • GMAB has an Altman-Z score of 2.51. This is not the best score and indicates that GMAB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • GMAB has a Altman-Z score of 2.51. This is in the better half of the industry: GMAB outperforms 66.67% of its industry peers.
  • GMAB has a debt to FCF ratio of 4.80. This is a neutral value as GMAB would need 4.80 years to pay back of all of its debts.
  • GMAB has a better Debt to FCF ratio (4.80) than 91.52% of its industry peers.
  • A Debt/Equity ratio of 0.88 indicates that GMAB is somewhat dependend on debt financing.
  • GMAB has a Debt to Equity ratio of 0.88. This is in the lower half of the industry: GMAB underperforms 73.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 2.51
ROIC/WACC1.46
WACC6.21%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that GMAB has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.02, GMAB is not doing good in the industry: 76.30% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.01 indicates that GMAB has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.01, GMAB is doing worse than 74.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GMAB Growth Analysis

3.1 Past

  • GMAB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.61%.
  • Measured over the past years, GMAB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.47% on average per year.
  • Looking at the last year, GMAB shows a quite strong growth in Revenue. The Revenue has grown by 19.25% in the last year.
  • GMAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.88% on average over the next years. This is quite good.
  • Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 12.86% on average per year.
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 14.34 indicates a correct valuation of GMAB.
  • Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 95.38% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.23, GMAB is valued a bit cheaper.
  • GMAB is valuated correctly with a Price/Forward Earnings ratio of 16.90.
  • GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 94.99% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.42. GMAB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.34
Fwd PE 16.9
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaply inside the industry as 94.22% of the companies are valued more expensively.
  • GMAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.53% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.66
EV/EBITDA 14.51
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
  • GMAB's earnings are expected to grow with 17.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)1.51
EPS Next 2Y5.16%
EPS Next 3Y17.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMAB Dividend Analysis

5.1 Amount

  • GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMAB Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (3/20/2026, 8:00:01 PM)

Premarket: 24.6 -0.5 (-1.99%)

25.1

-0.63 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners42.45%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.45B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts73.85
Price Target95.18 (279.2%)
Short Float %1.47%
Short Ratio4.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)6
Avg Revenue beat(8)225.98%
Revenue beat(12)10
Avg Revenue beat(12)350.6%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-51.63%
EPS NQ rev (3m)-51.63%
EPS NY rev (1m)-12.75%
EPS NY rev (3m)-18.56%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)0.67%
Valuation
Industry RankSector Rank
PE 14.34
Fwd PE 16.9
P/S 4.15
P/FCF 13.66
P/OCF 13.03
P/B 2.64
P/tB N/A
EV/EBITDA 14.51
EPS(TTM)1.75
EY6.97%
EPS(NY)1.49
Fwd EY5.92%
FCF(TTM)1.84
FCFY7.32%
OCF(TTM)1.93
OCFY7.67%
SpS6.04
BVpS9.5
TBVpS-5.9
PEG (NY)N/A
PEG (5Y)1.51
Graham Number19.34
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 2.51
F-Score4
WACC6.21%
ROIC/WACC1.46
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-15.07%
EPS Next 2Y5.16%
EPS Next 3Y17.95%
EPS Next 5Y9.88%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%
Revenue Next Year18.34%
Revenue Next 2Y16.58%
Revenue Next 3Y17.06%
Revenue Next 5Y12.86%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-1.15%
EBIT Next 3Y19.58%
EBIT Next 5Y4.81%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S -SP ADR / GMAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 6 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S -SP ADR?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for GMAB stock?

The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 14.34 and the Price/Book (PB) ratio is 2.64.


Can you provide the financial health for GMAB stock?

The financial health rating of GENMAB A/S -SP ADR (GMAB) is 6 / 10.